Skip to main content

Table 1 Patient characteristics at renal replacement therapy (RRT) inception, by era. All results are presented as median (interquartile range) or n(%)

From: Outcomes and practice patterns with hemodiafiltration in Shanghai: a longitudinal cohort study

   All No HDF HDF
N   9351 7207 2144
Age (years)*   58 (47, 71) 59 (47, 72) 56 (44, 67)
Gender* Male 5613 (60%) 4247 (59%) 1366 (64%)
  Female 3738 (40%) 2960 (41%) 778 (36%)
Cause of ESKF Primary 3892 (42%) 2969 (41%) 923 (43%)
  Secondary 3472 (37%) 2714 (38%) 758 (35%)
  Other 1987 (21%) 1524 (21%) 463 (22%)
BMI (kg/m2)*   22.2 (20.0, 24.8) 22.2 (20, 24.7) 22.5 (20.3, 25.0)
Weight (kg)*   61.6 (53.8, 69.7) 61.1 (53.5, 69.0) 63.2 (54.9, 71.8)
Height (m)*   1.67 (1.60, 1.72) 1.66 (1.60, 1.72) 1.68 (1.60, 1.73)
Hemoglobin (g/L) All patients 97.1 (81.9, 111.0) 97.1 (81.5, 111.0) 97.3 (82.0, 111.1)
  > = 3 x week RRT 97 (81, 111) 97 (81, 111) 97 (81, 111)
  > = 3 x week RRT & Kt/V > =1.2 98.2 (82.4, 111.9) 98.1 (82.2, 111.8) 96.5 (83, 112.1)
eGFR (mL/min/1.73m2) All patients 6.0 (4.5, 8.2) 6.0 (4.5, 8.3) 6.0 (4.5, 8.1)
  > = 3 x week RRT 6.1 (4.6, 8.5) 6.2 (4.6, 8.6) 6.0 (4.5, 8.2)
  > = 3 x week RRT & Kt/V > =1.2 6.3 (4.7, 8.6) 6.4 (4.7, 8.7) 6.2 (4.6, 8.3)
Creatinine Index (mg/kg/day) All patients* 21.2 (19.0, 23.7) 21.2 (18.9, 23.6) 21.5 (19.3, 23.9)
  > = 3 x week RRT* 21.2 (18.9, 23.5) 21.0 (18.8, 23.4) 21.4 (19.2, 23.8)
  > = 3 x week RRT & Kt/V > =1.2* 21.1 (18.9, 23.5) 20.9 (18.8, 23.3) 21.5 (19.3, 23.7)
Albumin (g/L) All patients* 36 (31.8, 40.2) 36 (31.5, 40) 36.8 (32, 40.9)
  > = 3 x week RRT* 36 (31, 40) 36 (31, 40) 36.5 (32, 40.7)
  > = 3 x week RRT & Kt/V > =1.2* 36.8 (32, 40.8) 36.4 (32.0, 40.3) 37.1 (32.9, 41.0)
Total Cholesterol (mM)   4.0 (3.3, 4.8) 4.0 (3.3, 4.8) 4.0 (3.3, 4.8)
Unadjusted Calcium*   2.21 (2.05, 2.39) 2.21 (2.05, 2.39) 2.23 (2.06, 2.41)
PO4 (mM) All patients 1.79 (1.40, 2.24) 1.79 (1.4,0 2.24) 1.77 (1.38, 2.21)
  > = 3 x week RRT 1.74 (1.37, 2.20) 1.75 (1.36, 2.20) 1.75 (1.38, 2
  > = 3 x week RRT & Kt/V > =1.2 1.76 (1.38, 2.2) 1.76 (1.37, 2.2) 1.77 (1.39, 2.22)
Frequency of RRT* < 3 x week 2721 (29%) 2525 (35%) 196 (9%)
  > = 3 x week RRT 6630 (71%) 4682 (65%) 1948 (91%)
Kt/V All patients* 1.29 (1.08, 1.53) 1.31 (1.10, 1.54) 1.24 (1.03, 1.47)
  > = 3 x week RRT* 1.26 (1.05, 1.48) 1.27 (1.06, 1.49) 1.24 (1.02, 1.47)
IDWG (% of weight) All patients* 3.3 (2.0, 4.5) 3.4 (2.1, 4.6) 3.1 (1.7, 4.2)
  > = 3 x week RRT* 3.2 (1.8, 4.3) 3.2 (1.9, 4.4) 3 (1.7, 4.2)
Hemoperfusion*   165 (2%) 27 (0.5%) 138 (6%)
Vascular access* AVF/AVG 4925 (53%) 3745 (52%) 1179 (55%)
  CVC / Other 4426 (47%) 3461 (48%) 965 (45%)
  1. Abbreviations: ESKF end-stage kidney failure, BMI body mass index, HDF hemodiafiltration, HP hemoperfusion, IDWG inter-dialytic weight gain, RRT renal replacement therapy, AVF arteriovenous fistula, AVG arteriovenous (prosthetic bridge) graft; CVC, central venous catheter
  2. *P < 0.05